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Abstract 
Neuroendocrine tumor cells (NETCs) are commonly observed in prostate cancer. Their presence 
is associated with castration resistance, metastasis and poor prognosis. Cellular and molecular 
mechanisms for NETC initiation and growth are unknown. TRAMP mice develop heterogeneous 
adenocarcinomas induced by expression of the SV40-T/t oncogene in prostate epithelial cells. 
Here, we demonstrate prostate tumors in TRAMP mice with a mixed genetic background are 
characterized mostly by atypical hyperplasia (AH) containing steroid receptor coac-
tiator-3-positive, androgen receptor-positive and synaptophysin-negative (SRC-3+/AR+/Syp-) 
cells. Few SRC-3+/AR-/Syp+ NETCs are present in their prostates. We generated TRAMP mice in 
which SRC-3 was specifically ablated in AR+/Syp- prostatic epithelial cells (termed PE3KOT mice). 
In these animals, we observed a substantial reduction in SRC-3-/AR+/Syp- AH tumor growth. 
There was a corresponding increase in SRC-3-/AR+/Syp- phyllodes lesions, suggesting SRC-3 
knockout can convert aggressive AH tumors with mostly epithelial tumor cells into less aggressive 
phyllodes lesions with mostly stromal tissue. Surprisingly, PE3KOT mice developed many more 
SRC-3+/AR-/Syp+ NETCs versus control TRAMP mice, indicating SRC-3 expression was retained 
in NETCs. In contrast, TRAMP mice with global SRC-3 knockout did not develop any NETC, in-
dicating SRC-3 is required for developing NETC. Analysis of cell-differentiating markers revealed 
that these NETCs might not be derived from the mature AR-/Syp+ neuroendocrine cells or the 
AR+/Syp- luminal epithelial tumor cells. Instead, these NETCs might originate from the 
SV40-T/t-transformed intermediate/progenitor epithelial cells. In summary, SRC-3 is required for 
both AR+/Syp- AH tumor growth and AR-/Syp+ NETC development, suggesting SRC-3 is a target 
for inhibiting aggressive prostate cancer containing NETCs. 
Key words: coactivator, SRC-3/NCOA3, prostate epithelium, carcinogenesis, neuroendocrine cell, transgenic 
mouse model. 
Introduction 
Prostate cancer (PCa) is the second leading cause 
of cancer death in American men [1]. A prostate tu-
mor usually exhibits multifocal lesions with various 
stages of differentiation patterns, suggesting that this 
disease is highly heterogeneous and contains multiple 
neoplastic clones within a single tumor [2]. Prostate 
adenocarcinoma arises from the prostatic epithelium 
and is the most common form of PCa [3]. The patho-
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logical grading system is established according to the 
histological differentiation stages of the cancerous 
epithelial cells. Terms such as well-differentiated 
(WD), moderately differentiated (MD) and poorly 
differentiated (PD) adenocarcinomas are used to de-
scribe the cancerous stages of prostate adenocarci-
nomas. Neuroendocrine (NE) PCa is a rare subtype, 
affecting about 2% of PCa patients. However, this 
percentage is significantly underestimated according 
to data from autopsy studies [4]. In fact, focal NE cell 
differentiation is commonly detected in PCa biopsies, 
and PCa with NE cells is usually associated with cas-
tration resistance, metastasis, resistance to chemo-
therapy and poor prognosis [5, 6]. The highly malig-
nant small cell lung cancer also consists of NE tumor 
cells and NE tumor cells are also seen in other types of 
cancer such as breast cancer. Previous studies have 
shown androgen depletion transforms prostate ade-
nocarcinoma cells into NE cells in culture and xeno-
graft models, suggesting hormone-targeted therapy 
may selectively drive the development of more ma-
lignant NE PCa [7-9]. However, the origin of neuro-
endocrine tumor cells in spontaneous PCa and the 
molecular mechanisms responsible for development 
of NE tumors are completely unknown. 
The transgenic adenocarcinoma of the mouse 
prostate (TRAMP) is a mouse model in which the rat 
probasin promoter (PB) drives the expression of the 
simian vacuolating virus 40 T/t antigens (SV40-T/t) 
in prostatic epithelial cells for induction of PCa 
through inhibiting p53, retinoblastoma (RB) and pro-
tein phosphatase 2A (PP2A) tumor suppressors [10]. 
Similar to human PCa, TRAMP mice develop hetero-
geneous prostate tumors with various differentiation 
stages, including both types of adenocarcinoma 
termed atypical hyperplasia (AH) as well as neuro-
endocrine (NE) tumors [11, 12]. As in men, prostate 
tumor phenotypes in TRAMP mice may switch from 
AH to aggressive NE phenotype upon castration [13]. 
Phyllodes-like lesions (PHY) characterized by stag-
horn luminal patterns containing hypercellular stro-
ma are also observed in TRAMP mice [14]. The PHY 
tumor of the prostate is a rare neoplasm with poorly 
understood pathogenesis [15]. Overall, TRAMP mice 
offer an advantageous model for studying PCa with 
different neoplasm types: AH, NE and PHY tumors. 
Steroid receptor coactivator-3 (SRC-3, AIB1, 
ACTR, or NCOA3) is a member of the p160 SRC fam-
ily. Serving as an adapter to recruit chroma-
tin-remodeling proteins, SRC-3 mediates transcrip-
tional activities of nuclear hormone receptors such as 
estrogen receptor (ER) and androgen receptor (AR), as 
well as other transcription factors such as E2F-1, 
PEA3, AP-1 and NF-kB [16, 17]. Several studies have 
demonstrated that overexpression of SRC-3 induces 
breast carcinogenesis, while knockout of SRC-3 inhib-
its oncogene and chemical carcinogen-induced 
mammary gland tumorigenesis [18-22]. In human 
prostate tumors, SRC-3 expression correlates posi-
tively with tumor grade and stage [23]. In PCa cell 
lines, SRC-3 upregulates cell cycle genes, multiple 
components of the IGF-I/Akt pathway, MMP2 and 
MMP13 – in all, promoting cell proliferation, migra-
tion and invasion [24-26]. These in vitro studies sug-
gest that SRC-3 may play an important role in pro-
moting PCa. 
We have shown that global knockout of SRC-3 in 
TRAMP mice significantly inhibits prostate tumor 
growth and also arrests PCa progression at a 
well-differentiated stage [27]. Although this study 
suggests targeting SRC-3 may suppress prostate car-
cinogenesis, this global SRC-3 knockout model has its 
pitfalls. First, SRC-3 null mice have a significantly 
reduced IGF-I level in blood, which may indirectly 
affect prostate tumorigenesis. Moreover, knockout of 
SRC-3 in the prostate stromal cells may also indirectly 
impede prostate epithelial carcinogenesis through 
paracrine regulatory pathways between epithelium 
and stroma [28]. In the present study, we developed 
prostate epithelial cell-specific SRC-3 knockout mice 
and further illustrated the specific role of SRC-3 in 
development of different types of prostate adenocar-
cinoma. We found that specific ablation of SRC-3 me-
diated by the PB-Cre transgene in the AR-positive 
(AR+) prostatic epithelial cells, predominantly pros-
tatic luminal epithelial cells (LECs), slows down the 
growth and progression of AR+ AH tumors in 
TRAMP mice, but significantly enhances the devel-
opment of the more aggressive SRC-3-expressing NE 
tumors and the less aggressive SRC-3-negative PHY 
tumors. Interestingly, we found that these SRC-3+ NE 
tumors likely originate from neither the mature NE 
epithelial cells nor the LEC-like tumor cells, but from 
the epithelial intermediate/progenitor cells that 
co-express SRC-3, SV40-T/t antigens, cytokeratin 5 
(K5), p63 and Syp. Furthermore, global knockout of 
SRC-3 in TRAMP mice completely suppresses the 
development of Syp+ NE tumors, indicating SRC-3 is 
absolutely required for NE tumor development from 
these intermediate/progenitor cells. 
Materials and Methods 
Mice. The floxed SRC-3 mouse line (SRC-3f/f) 
was generated in our lab as described previously [29] 
and they are in a mixed 129SvEv/C57BL/6J strain 
background. The TRAMP (PB-SV40-T/t) transgenic 
mouse line in C57BL/6J strain background (provided 
by Dr. Norman Greenberg) and the ARR2PBi-Cre 
(PB-Cre) transgenic mouse line in FVB strain back-
ground were described previously [10, 30]. TRAMP 
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mice were first crossbred with PBi-Cre mice and then, 
their PB-Cre;PB-SV40-T/t offspring were crossbred 
with SRC-3f/f mice. The PB-Cre;SRC-3f/+;PB-SV40-T/t 
offspring were then bred with SRC-3f/f mice again to 
generate PB-Cre;SRC-3f/f;PB-SV40-T/t testing and 
SRC-3f/f;PB-SV40-T/t control mice with comparable 
genetic background for experiments. For convenience, 
we designated the testing mice as 3PEKOT (SRC-3 
prostate epithelial knockout in TRAMP) mice and the 
control mice as 3FloxT (floxed SRC-3 in TRAMP) 
mice. For genotype analysis, genomic DNA samples 
were prepared as DNA templates and PCR reactions 
were performed using primer pairs specific to PB-Cre 
or PB-SV40-T/t transgene and to SRC-3 wild type 
(WT), floxed, or deleted allele as described previously 
[10, 29, 30]. Animal protocols were approved by the 
Animal Care and Use Committee of Baylor College of 
Medicine. 
Tissue examination. 18-, 24- and 30-week-old 
male 3FloxT and 3PEKOT mice were weighed and 
euthanized. Their lower urogenital tracts were re-
moved en bloc and the weight of urogenital tract was 
measured. The prostate tissue was then dissected out 
in a Petri dish containing phosphate-buffered saline 
(PBS). The prostate tumor tissues were isolated and 
blotted gently with paper towel to remove excess 
fluid and PBS. The weight of prostate tumors was 
then measured, and tumor tissues were then fixed in 
4% paraformaldehyde at 4oC overnight for tissue 
process. 
Histological examination and immunohisto-
chemistry (IHC). Fixed prostate tissues and tumors 
were embedded in paraffin and paraffin sections were 
processed for H&E staining and immunostaining as 
described previously [27]. Immunostaining was per-
formed using primary antibodies against SRC-3 (Cell 
Signaling, #2126), AR (Santa Cruz, sc-816), Syp (Invi-
trogen, 18-0130), SV40 T antigen (BD Biosciences, 
554149), Ki67 (BD Biosceinces, 550609) and K5 (Co-
vance, PRB160P). Secondary antibodies for IHC were 
biotinylated anti-Rabbit IgG and biotinylated an-
ti-mouse IgG (Vector labs) used at 1:400 dilution. The 
signal was enhanced using the VECTASTAIN ABC 
system and visualized with DAB kit. The slides were 
counterstained with Harris Modified Hematoxylin 
and mounted with Permount. For double immuno-
histofluorescence, Tyramide Signal Amplification kit 
(Life technologies) was used per manufacturer’s in-
structions. For Syp, SV40 T and K5 triple immmuno-
histofluorescence, slides were incubated with Syp 
antibody overnight, washed with PBST and then in-
cubated with biotinylated anti-Rabbit monovalent Fab 
antibodies for 1 hour at room temperature. The slides 
were further incubated with tertiary streptavidin HRP 
antibody for 1 hour at room temperature and the 
green signal was visualized with TSA kit #22 (Life 
technologies). Prior to incubation with the SV40 T 
antibody, the slides were blocked with streptavi-
din/biotin blocking kit (Vector Lab) followed by 3% 
H2O2 treatment. The slides were then blocked by 
MOM kit (Vector Lab) for 1 hour at room temperature 
and incubated with SV40 T antibody overnight at 4oC. 
The secondary antibody used was biotinylated an-
ti-Mouse IgG followed by the tertiary streptavidin 
HRP antibody. The red signal was visualized with 
TSA kit #25 (Life technologies). Finally, the slides 
were incubated with the streptavidin/biotin blocking 
reagent, treated with 3% H2O2, incubated with K5 
antibody overnight at 4oC followed by incubation 
with HRP-goat anti-Rabbit IgG for 1 hour at room 
temperature. The blue signal was then detected with 
TSA kit #17 (Life technologies). 
Results 
Conditional knockout of SRC-3 in prostatic 
epithelial cells of TRAMP mice 
In order to investigate the cell autonomous role 
of SRC-3 in prostate carcinogenesis, we generated 
3PEKOT (PB-Cre;SRC-3f/f;PB-SV40T/t) and 3FloxT 
(SRC-3f/f;PB-SV40T/t) mice with a comparable mixed 
strain background by crossbreeding PB-Cre, SRC-3f/f 
and TRAMP (PB-SV40-T/t) mouse lines [10, 29, 30]. In 
3PEKOT male mice, the PB-Cre transgene was only 
expressed in the prostate epithelial cells [29, 30], and, 
as such, specified deletion of the floxed SRC-3 alleles 
only in these cells. Genotype analysis detected a 
strong band representing the mutant allele with 
SRC-3 deletion from the prostate DNA samples of 
18-week-old 3PEKOT mice, while a much lighter band 
representing the floxed SRC-3 allele was also detect-
ed. This later band indicated the floxed SRC-3 alleles 
that were not deleted in the prostate stromal cells 
lacking PB-Cre expression. In 18-week-old 3FloxT 
control mice harboring the PB-SV40-T/t transgene but 
not the PB-Cre transgene, only the floxed SRC-3 al-
leles were detected from the prostate DNA samples 
(Fig. 1A). SRC-3 protein was detected by IHC in the 
luminal epithelial cells (LECs) with slightly weaker 
staining in some basal epithelial cells (BCs) in the 
prostates of 8-week-old 3FloxT control mice. On the 
contrary, SRC-3 protein was absent in LECs in the 
prostates of 3PEKOT mice, although SRC-3 was still 
present in some BCs (Fig. 1B). In addition, the inten-
sity of SV40-T immunoreactivity and the total number 
of SV40-T-positive prostatic epithelial cells were 
comparable between 3FloxT and 3PEKOT mice at 8 
weeks of age (Fig. 1C). These results demonstrate that 
SRC-3 is specifically and efficiently ablated in the 
prostate LECs of 3PEKOT mice and SRC-3 ablation 
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does not affect the PB-SV40T/t transgene expression 
during the prostate tumorigenesis induced by 
SV40-T/t antigens. 
Gross weights of prostate tumors in 3PEKOT 
and 3FloxT mice are similar 
TRAMP mice develop multifocal and aggressive 
tumors by 24 weeks of age and generally survive up 
to 30 weeks [27]. Therefore, we evaluated prostate 
tumor growth in 3PEKOT and 3FloxT mice at 18, 24 
and 30 weeks of age. We found that there was no dif-
ference in body weight between 3PEKOT and 3FloxT 
mice at any time point (Fig. 2A). The average genito-
urinary tract (GU) weight trended lower in 3PEKOT 
versus 3FloxT mice at 24 and 30 weeks (Fig. 2B). 
However, these GU weight differences did not reach 
statistical significance. Indeed, further dissection in-
dicated no weight difference between the prostates of 
3PEKOT and 3FloxT mice at 24 and 30 weeks (Fig. 
2C). Moreover, morphological examination of GUs 
and dissected prostates revealed that prostate tumors 
developed in both 3PEKOT and 3FloxT mice (Fig. 2D 
and E). Overall, these results demonstrate similar 
gross tumor weight in both experimental and control 
groups. 
Progressive changes of prostate tumor 
phenotypes from atypical hyperplasia to 
neuroendocrine and phyllodes-like tumors in 
3PEKOT mice 
 There are three types of tumors that develop in 
the TRAMP model: atypical hyperplasia (AH), neu-
roendocrine (NE) tumors, and phyllodes-like (PHY) 
tumors [12]. We identified each of these tumor types 
in 3PEKOT and 3FloxT mice. AH regions contained 
mostly AR+ cells and were devoid of Syp+ cells. NE 
tumor regions contained exclusively Syp+ tumor cells 
completely negative for AR. PHY tumor regions were 
characterized by significant stromal cellularity un-
derlying linearly-distributed epithelial cells. Many 
AR+ cells were detectable in the stromal compart-
ment, while almost all epithelial cells were AR+ in the 
PHY tumor regions (Fig. 3A). We detected SRC-3 
protein by IHC in the epithelial cells of AH tumor 
regions and the Syp+ cells of NE tumor regions of 
30-week-old 3FloxT mice. We also detected SRC-3 
protein in all Syp+ cells of NE tumor regions and the 
stromal cells of PHY tumor regions, but not in the 
epithelial tumor cells of AH regions and PHY regions 
of 30-week-old 3PEKOT mice owning to 
PB-Cre-mediated SRC-3 knockout in these cell types 
(Fig. 3A and data not shown).  
 
 
Figure 1. Conditional knockout of SRC-3 in prostatic epithelial cells of TRAMP mice. A. Deletion of the floxed SRC-3 alleles in the prostates of 3PEKOT mice. 
Genomic DNA samples were prepared from prostate tumors of 24-week-old 3FloxT (n=3) and 3PEKOT (n=3) mice or from a WT mouse prostate and used as templates for 
PCR. DNA fragments representing the PB-SV40-T/t and PB-Cre transgenes and the WT, floxed and deleted SRC-3 alleles were amplified using allele-specific primer pairs. B. IHC 
for SRC-3 (brown) in the prostate sections prepared from 8-week-old 3FloxT and 3PEKOT mice. C. IHC for SV40 T antigen (brown) in the prostate sections prepared from 
8-week-old 3FloxT and 3PEKOT mice. The percentage of SV40 T-positive was calculated by dividing the number of positive epithelial cells by the number of total epithelial cells 
per imaging field. Three random imaging fields per section and sections from 5 mice were assessed. 
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Figure 2. Characterization of prostate tumor growth in 3PEKOT and 3FloxT mice. A. Similar body weights of 3PEKOT and 3FloxT mice (n=10 for each group) at 
ages indicated. B. The genitourinary tract (GU) weights of 3PEKOT and 3FloxT mice at different ages (n=10 in each group). GU weight trended lower in 3PEKOT versus 3FloxT 
mice at 24 and 30 weeks, but the difference did not reach statistical significance. C. The average prostate tumor weights of these two groups of mice were also not statistically 
different. D. The macroscopic gross pictures of the upper genitourinary tracts of 24-week-old 3PEKOT and 3FloxT mice. Arrows indicate prostate tumors. E. The macroscopic 
gross pictures of dissected prostates with tumors of 24-week-old 3PEKOT and 3FloxT mice. Of note, one of the anterior lobs in this 3FloxT mouse has bigger tumor, which was 
not consistently observed in all mice at this stage. 
 
Figure 3. Increased NE tumor incidence in 3PEKOT mice at 30 weeks of age. A. Three types of tumor lesions developed in TRAMP mice, including atypical hyper-
plasia (AH), neuroendocrine tumor (NE) and phyllodes (PHY). AH tumor cells express AR and SRC-3 but not Syp. NE tumor cells express Syp and SRC-3 but not AR. PHY tumor 
cells express AR but not Syp. The images of AH were taken from a tumor section of 3FloxT mouse, while the images of NE and PHY were taken from tumor sections of 3PEKOT 
mice. B. The frequency of each tumor type in the tumors of 24 and 30-week-old 3FloxT and 3PEKOT mice. See text for the results of statistical analysis. 
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 We evaluated the frequency of each tumor type 
in the prostates of 24 and 30-week-old 3FloxT and 
3PEKOT mice. At 24 weeks, AH was the principal 
prostate cancer type developed in the vast majority of 
3FloxT (7/8) and 3PEKOT (7/8) mice. Only one out of 
eight 3FloxT mice developed NE tumor and one out of 
eight 3PEKOT mice developed PHY tumor as the 
dominant histological pattern in the prostate tumor 
(Fig. 3B). At 30 weeks, we found that 91.7% (11/12) of 
3FloxT mice had prostate tumors with a principally 
AH phenotype, while only a single mouse out of 12 
mice (8.3%) had a principally NE tumor phenotype. 
Moreover, we observed no PHY tumors in 3FloxT 
mice. On the contrary, only 42% (8/19) 3PEKOT mice 
had tumors in which the principal histological pattern 
was AH. Interestingly, 26% (5/19) of these animals 
developed principally NE tumors, while 32% (6/19) 
developed principally PHY tumors (Fig. 3B). A 
Chi-squared test revealed that, while there was no 
significant difference in cancer type incidence be-
tween 3FloxT and 3PEKOT mice at 24 weeks, there 
was a significant difference between two groups at 30 
weeks, χ2 (2, N =31) = 7.967, p=0.019, indicating that 
3FloxT mice preferentially develop AH lesions while 
3PEKOT mice preferentially develop NE and PHY 
lesions at 30 weeks. These results demonstrate that 
3FloxT control mice initially develop AR+ AH tumors 
and also maintain the same type of tumors for a long 
time. However, 3PEKOT mice initially develop AR+ 
AH tumors in their prostates, but this tumor pheno-
type in most mice was switched to either AR-/SRC-3+ 
NE tumors or AR+/SRC-3- PHY tumors. Again, 
SRC-3 is only expressed in the stromal cells of PHY 
tumors. 
Deletion of SRC-3 slows down prostate AH 
tumor growth and progression 
Because AH tumors have characteristics of LECs 
that express AR, we decided to first analyze these AH 
tumors and evaluate the impact of SRC-3 deletion in 
these AH tumor cells. We compared prostate AH le-
sions collected from 12-, 18- and 24-week-old 3FloxT 
and 3PEKOT mice. From histological examination of 
H&E stained sections, we found that AH tumor pro-
gression was slower in 3PEKOT mice (Fig. 4A).  
 
 
 
Figure 4. Slower progression of AH tumors in 3PEKOT mice. A. H&E-stained prostate tumor sections prepared from 3PEKOT and 3FloxT mice at different ages. B. 
IHC for SRC-3 (brown) in AH tumors of 3PEKOT and 3FloxT mice at different ages. C. Representative images of IHC for Ki67 (brown) in 24-week-old 3FloxT and 3PEKOT 
mice. D. Proliferation indexes of AH tumor cells in 3PEKOT and 3FloxT mice at different ages. Six mice were assayed for each data point. The percentage of Ki67+ cells was 
calculated by dividing the number of ki67+ tumor cells by total number of tumor cells per imaging field. E. Double immunohistofluorescent staining for SRC-3 (green) and AR 
(red) in prostate tumors of 24-week-old 3FloxT and 3PEKOT mice. Some SRC-3+ tumor cells are AR-. 
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At 12 weeks, 3FloxT mice developed PIN lesions, 
while 3PEKOT mice contained both hyperplasia and 
prostate intraepithelial neoplasia (PIN) lesions. At 18 
weeks, 3FloxT mice developed well-differentiated 
adenocarcinoma (WDA), while tumors in 3PEKOT 
mice were still at PIN stage. At 24 weeks, high-grade 
moderately differentiated adenocarcinoma (MDA) 
was observed in 3FloxT mice, while tumors in 
3PEKOT were arrested at WDA stage. SRC-3 protein 
was detected in all LEC-like AH tumor cells in 3FloxT 
mice throughout stages from 12 to 24 weeks (Fig. 4B). 
However, in the prostates of 3PEKOT mice SRC-3 
protein was ablated in most AH tumor regions. In the 
regions where SRC-3 was efficiently ablated in LECs, 
the tumor progression was halted at WDA stage (Fig. 
4B). To determine if cell proliferation was reduced in 
the AH regions of 3PEKOT mice compared to 3FloxT 
mice, we performed IHC for Ki67. We found that the 
percentage of Ki67+ cells in the AH tumor regions in 
3PEKOT mice was not significantly changed at 8 and 
12 weeks of age, but did significantly decreased at 18 
and 24 weeks of age when compared with that of 
3FloxT mice (Fig. 4C and D). Interestingly, in the AH 
tumors of 3FloxT mice, the proliferation index in-
creased incrementally as age increased. On the con-
trary, in the AH tumors of 3PEKOT mice, the prolif-
eration index decreased as age increased from 12 
weeks (Fig. 4D). Furthermore, double immunohisto-
fluorescent staining of AR and SRC-3 revealed that 
SRC-3 was expressed in all AR+ AH tumor cells in 
3FloxT mice. Knockout of SRC-3 in these cells caused 
higher AR immunoreactivity, suggesting that the AH 
tumors in 3PEKOT mice might be more differentiated 
(Fig. 4E). Moreover, in some AH tumors of 3FloxT 
mice, a small number of SRC-3+/AR- cells can be 
identified, supporting the notion that tumors with 
SRC-3 expression have a less differentiated pheno-
type. Taken together, these results demonstrate that 
ablation of SRC-3 in AH tumor cells decreased cell 
proliferation and prevented the progression of these 
tumors. 
SRC-3 is required for the development of 
prostate neuroendocrine tumor 
 In agreement with the results shown in Fig. 3B, 
IHC for AR and Syp identified AR+/Syp- AH tumors 
in all of the 3FloxT mice at 30 weeks of age, but fre-
quent AR-/SyP+ NE tumors in 3PEKOT mice at 30 
weeks of age (Fig. 5A). To define the general contri-
bution of SRC-3 in development of NE tumors, we 
analyzed AR and Syp expression in prostate tumors 
isolated from 24- and 30-week-old TRAMP;SRC-3-/- 
mice with global knockout of SRC-3 (6 mice at each 
age group). Importantly, we only found AR+/Syp- 
AH tumors in these mice (Fig. 5A and data not 
shown), indicating that SRC-3 is required for the de-
velopment of NE tumor in TRAMP mice. 
Since Cre is not expressed in NE cells in the 
prostates of PB-Cre transgenic mice [30], we hypothe-
sized that the floxed SRC-3 alleles in the NE tumors 
developed in 3PEKOT mice at 30 weeks were not de-
leted. Indeed, IHC revealed that almost all of these 
AR-/Syp+ NE tumor cells still expressed SRC-3 pro-
tein, as well as the SV40-T antigen (Fig. 5B). These 
results clearly indicate that SRC-3 is essential for the 
development of NE tumors induced by inhibition of 
p53, Rb and PP2A by SV40-T/t antigens in the mouse 
prostate and this essential role of SRC-3 in the devel-
opment of NE tumor is independent of AR. 
Neuroendocrine tumor cells may be derived 
from the progenitor cell subpopulation 
To explore the cellular origin of the 
SRC-3-dependent NE tumors, we performed double 
immunofluorescent staining for SV40-T antigen that 
induces tumorigenesis and the Syp that marks the 
neuroendocrine cell linage to identify the cell type 
that NE tumors may come from. At the early stage (8 
weeks of age) of prostate tumorigenesis in TRAMP 
mice when the prostate still had normal morphology, 
we only detected Syp+ NE cells in three out of seven 
3PEKOT mice, indicating these NE cells are extremely 
rare in the prostate epithelium at this stage. Im-
portantly, these well-scattered NE cells did not ex-
press SV40-T, indicating these individual mature NE 
cells are normal NE cells and not the originating cells 
of NE tumors in 3PEKOT mice. At this stage, SV40-T 
was only detected in some of the Syp- epithelial cells 
(Fig. 6A). These observations raised the possibility 
that NE tumor cells might be derived and differenti-
ated from progenitor-like epithelial cells that express 
SV40-T, since there are stem cells residing in the p63+ 
BC population in the prostate of adult mouse and 
these stem cells are capable of generating basal, lu-
minal and NE epithelial cells [31-34]. To investigate 
this possibility, we immunostained Syp, SV40-T, p63 
and K5 in prostate sections prepared from 
8–12-week-old 3PEKOT and 3FloxT mice. p63 and K5 
are prostate BC markers that are also expressed in 
epithelial progenitor and intermediate progenitor 
cells [31-34]. We found SV40-T expression in a small 
subpopulation of K5+ BCs in the prostate epithelium 
of both 3PEKOT and 3FloxT mice (n=6 for each 
group), suggesting that K5+ basal/progenitor cells 
may be transformed by the SV40-T/t oncogenic pro-
teins (Fig. 6B). We detected small clusters of Syp+ 
cells, and some of these cells co-expressed SV40-T or 
K5 with Syp in all examined 3PEKOT mice (Fig. 6C 
and D). However, Syp and K5 double positive cells 
were not observed in the prostates of 3FloxT mice at 
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the same stage (data not shown). Moreover, we also 
identified cells with weaker Syp and p63 im-
munostaining signals, another feature of intermediate 
cells, in the prostates of 3PEKOT mice (Fig. 6E). More 
importantly, by performing triple immunofluorescent 
staining we confirmed a small subpopulation of cells 
that indeed co-express Syp, K5 and SV40-T in the 
prostates of 3PEKOT mice (Fig. 6F). Taken together, 
these results indicate that Syp and SV40-T begin to 
express in some of the epithelial intermediate pro-
genitor cells derived from p63+/K5+ progenitor cells. 
These SV40-T/t-transformed intermediate progenitor 
cells but not the mature NE cells may be the originat-
ing cells of NE tumors observed in TRAMP mice. As 
expected, the Syp+ cells in the large NE tumor regions 
no longer express K5 and p63 (Fig. 6G and data not 
shown), supporting the notion that these tumor cells 
are differentiated from SV40-T, p63 and K5 triple 
positive tumor progenitor cells. 
 
 
 
Figure 5. SRC-3+ NE tumors are commonly observed in 30-week-old 3PEKOT mice. A. IHC for AR and Syp (brown) in tumor sections of 30 week-old 3FloxT, 
3PEKOT and SRC-3-/-;TRAMP mice. AH, atypical hyperplasia; NE, neuroendocrine tumor. B. IHC for SV40 T antigen, AR, SRC-3 and Syp (brown) in adjacent sections of a NE 
tumor from a 30-week-old 3PEKOT mouse.  
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Figure 6. NE tumors may be derived from intermediate progenitor cells expressing SV40-T antigen. A. Double immunostaining for Syp (green) and SV40-T 
antigen (red) in the prostate tissue section of an 8-week-old 3PEKOT mouse. Arrows indicate immunostaining signals for Syp or SV40-T. B. Double immunostaining for SV40-T 
(green) and K5 (red) in a prostate tissue section of a 3PEKOT mouse. Arrows indicate the same cell positive for SV40-T, K5 and DAPI staining. C. Double immunostaining for 
Syp (green) and SV40-T (red) in a prostate tissue section of a 3PEKOT mouse. Arrows indicate double positive cells in the cluster of NE cells. D. Double immunostaining for Syp 
(green) and K5 (red) in the prostate section of a 3PEKOT mouse. Arrows indicate the double positive cells. E. Double immunostaining for Syp (green) and p63 (red). Arrows 
indicate the Syp+ cell with weak p63 immunoreactivity. F. Triple immunostaining for Syp (green), SV40-T (red) and K5 (blue) in a prostate section of 12-week-old 3PEKOT 
mouse. Arrows indicate the triple positive cells. G. Double immunostaining for K5+ BCs and Syp+ NE tumor cells in a prostate of 30-week-old 3PEKOT mouse with a large NE 
tumor. 
 
Discussion 
In this study, we generated 3FloxT and 3PEKOT 
mice and demonstrated that specific ablation of SRC-3 
in the AR+ prostate epithelial cells does not affect 
SV40-T/t expression driven by the andro-
gen-responsive rat probasin promoter, which is con-
sistent with our previous study showing SRC-3 is not 
essential for androgen-regulated normal prostate re-
generation and gene expression in mice [27]. We 
found that deletion of SRC-3 significantly reduced the 
proliferation and growth of the AR+ AH tumor cells 
in 3PEKOT mice versus 3FloxT mice. This result is 
consistent with our previous study showing global 
knockout of SRC-3 in TRAMP mice did not affect AH 
tumor initiation but restricted its growth and pro-
gression [27]. Because TRAMP;SRC-3-/- mice used in 
the previous study had multiple other phenotypes 
such as significantly decreased body weight and cir-
culating levels of IGF-I and IGFBP-3 [27, 35, 36], we 
were unable to distinguish the intrinsic role of SRC-3 
in the prostate tumor cells from the systemic or local 
stromal influence. In the current study, inhibition of 
AH tumor growth by specific knockout of SRC-3 in 
the AR+ prostate epithelial cells in 3PEKOT mice 
clearly indicates the cell-autonomous role of SRC-3 in 
promotion of AR+ tumor cell growth. Since androgen 
signaling is normal in the prostate of SRC-3-/- mice 
[27], the inhibited AH tumor growth in 3PEKOT mice 
is unlikely attributed to a changed AR function. In-
stead, previous in vitro studies have shown that 
SRC-3 promotes prostate cancer cell proliferation 
through enhancing the activity of PI3K-Akt signaling 
pathway and upregulating cell cycle genes [24, 25]. 
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PHY tumors are fibroepithelial tumors com-
posed of an epithelial and stromal component. Ap-
proximately 70% of PHY tumors are benign [37]. We 
did not find PHY tumors in 3FloxT mice, but observed 
PHY tumors in 32% of 3PEKOT mice. In these PHY 
tumors, SRC-3 was present in the stromal cells but 
absent in the SRC-3 knockout epithelial tumor cells. It 
is currently unclear whether SRC-3 expressed in these 
stromal cells plays a role in PCa development. Fur-
thermore, the increased incidence of SRC-3-/AR+ 
epithelial tumor cells in PHY lesions also correlated 
with decreased incidence of SRC-3-/AR+ AH tumors 
in 3PEKOT mice. These observations suggest knock-
out of SRC-3 may help to convert the more malignant 
AH tumors into the less malignant PHY tumors, or 
just give them more space to grow. 
The most interesting finding of this study is the 
extensive development of neuroendocrine tumors in 
3PEKOT mice and the fact that these tumor cells still 
express SRC-3 owning to their escape from 
PB-Cre-mediated deletion of the floxed SRC-3 alleles 
in this cell lineage. Together with our results showing 
TRAMP;SRC-3-/- mice do not develop neuroendocrine 
tumor, we conclude that SRC-3 plays a permissive 
role in neuroendocrine tumor development in 
3PEKOT mice. Since the evolution to a neuroendo-
crine phenotype in human PCa is associated with 
particularly aggressive castration-resistant prostate 
cancer (CRPC) [38], our findings that SRC-3 promotes 
neuroendocrine tumor development in TRAMP mice 
should aid in understanding mechanisms that pro-
mote human PCa progression into aggressive CRPC 
in the setting of androgen ablation therapy. 
Because NE cells are observed in more than 30% 
of human primary PCa and the number of NE cells 
positively correlates with Gleason Score and CRPC 
cases, it is important to find the origin of these can-
cer-associated NE cells. In general, NE cells are 
thought to originate from neural crest-derived pro-
genitors [39]. However, clinical analyses of the benign 
prostate implicate local epithelial stem cells as NE 
precursors [40, 41]. Moreover, in vitro studies have 
suggested NE tumor cells in PCa arise from 
trans-differentiation of epithelial adenocarcinoma 
with a luminal phenotype [42, 43]. In TRAMP mice, it 
has been shown that the BrdU-retaining cells after 
androgen deprivation express SV40-T antigen and 
Syp, suggesting NE tumor cells arise independent of 
androgen-deprivation [44]. In TRAMP mice with a 
FVB strain background, NE precursor lesions can be 
detected at 4 weeks of age [12]. These studies suggest 
that NE tumor cells can be derived either from 
AR+/Syp- adenocarcinomas through 
trans-differentiation or from unknown progenitor 
cells. 
In this study, we showed that differentiated in-
dividual Syp+ NE cells do not express SV40-T antigen 
and thus, these NE cells are not the parent cells of the 
Syp+/SV40-T+ NE tumor cells in TRAMP mice. We 
also clearly showed that SRC-3 is efficiently knocked 
out in AR+/Syp- AH and PHY tumor cells in 3PEKOT 
mice, while the Syp+/AR- NE tumor cells maintain 
SRC-3 expression. These findings prove that the 
SRC-3+ NE tumor cells cannot be trans-differentiated 
from the SRC-3 knockout AR+/Syp- tumor cells. In-
stead, our data indicate that the AR-/Syp+/SRC-3+ 
NE tumor cells originate from SV40-T/t-transformed 
progenitor cells. First, at early stages of PCa devel-
opment in adult 3PEKOT mice, we found that 
Syp+/SV40-T+ NE cells always form clusters con-
taining several such cells, but singly scattered normal 
NE cells never express SV40-T antigen, suggesting 
these clustered NE cells might be the transformed 
pioneers of NE tumors. Second, we found certain cells 
in the Syp+/SV40-T+ clusters co-express p63, a 
marker of BCs that contain prostate epithelial pro-
genitors in adult mice. A previous study also identi-
fied SV40-T expression in a subset of p63+ BCs in 
TRAMP mice [45]. However, p63 is not expressed in 
bigger Syp+ NE lesions seen at later stages in tumor 
development. These results suggest the 
p63+/Syp+/SV40-T+ cells are progenitors derived 
from the p63+ stem-like cells in the BC layer. Finally, 
the progenitor feature of these p63+/Syp+/SV40-T+ 
cells is further supported by their relatively weak ex-
pression of K5, which is a marker for basal and in-
termediate epithelial cells and cancer stem cells in the 
prostate [46]. The aforementioned analysis was made 
possible by co-expression of Cre and SV40-T/t in a 
subpopulation of basal/intermediate cells. It is note-
worthy that overlap between expression of these 
transgenes was not 100% given sequence difference in 
the upstream androgen response elements and the 
stochastic nature of promoter activation in different 
transgenic mouse lines. 
In summary, our results suggest that SV40-T/t 
antigens start to express in a subset of p63+/K5+ in-
termediate cells derived from adult prostate epithelial 
stem-like cells in TRAMP mice. The inhibition of p53, 
RB and PP2A tumor suppressors by SV40-T/t anti-
gens in these intermediate cells causes uncontrolled 
expansion of these cancer stem-like cells. In the pres-
ence of SRC-3, the majority of these cells undergo 
partial differentiation into AR+/Syp-/SRC-3+ lu-
minal-like AH tumor cells, while a small population 
of these cells undergo partial differentiation into 
AR-/Syp+/SRC-3+ NE tumor cells. When SRC-3 is 
conditionally knocked out by the AR-dependent ex-
pression of the PB-Cre transgene in the AR+/Syp- AH 
tumor cell lineage of 3PEKOT mice, the proliferation 
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of these tumor cells is inhibited, leading to a switch to 
PHY tumors with dominant stromal accumulation. 
However, SRC-3 cannot be knocked out in AR-/Syp+ 
NE tumor cell lineage in 3PEKOT mice, allowing NE 
tumors rapidly develop and progress into large ma-
lignant NE tumors. Because SRC-3 is required for AH 
tumor growth and NE tumor development, global 
knockout of SRC-3 in TRAMP mice can effectively 
inhibit the growth and progression of AH tumors [27] 
and the development of NE tumors (data in this 
study). These findings have important basic and 
translational scientific implications. More specifically, 
our model suggests that the highly aggressive PCa 
with NE tumor cells may be originated from undif-
ferentiated or poorly differentiated intermediate 
progenitor cells that can generate both AH and NE 
tumor cells. Thus, antiandrogen therapy may only 
inhibit the growth of partially differentiated AR+ AH 
tumor cells, but not the AR- progenitors and the 
AR-/Syp+ NE tumor cells, allowing these cells to 
progress into metastatic CRPC. Furthermore, our 
findings also suggest that SRC-3 may serve as a mo-
lecular target to control both AH and NE tumor 
growth and progression.  
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